InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

PHASE2TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

March 30, 2022

Conditions
COVID-19Lymphocytopenia
Interventions
DRUG

Interleukin-7

Intramuscular (IM) administration of CYT107 at 3 μg/kg followed, after 48hrs of observation, by 10 μg/kg twice a week for 2 weeks or

DRUG

Placebos

Intramuscular (IM) placebo (normal saline) at the same frequency

Trial Locations (13)

B18 7QH

Sandwell Birmingham Hospital, Birmingham

Unknown

Sandwell Birmingham Hospital, Birmingham

Royal Preston Hospital, Preston

Sunderland Royal Hospital, Sunderland

BD9 6RJ

Bradford Institute for Health Research, Bradford

LS9 7TF

ST JAMES's UNIVERSITY HOSPITAL, Leeds

ME7 5NY

Medway Maritime Hospital, London

SE1 9RS

Guy's and St Thomas' NHS Foundation Trust, London

SE5 9RS

King'S College Hospital, London

M23 9LT

Wythenshawe Hospital/ Manchester Royal Infirmary, Manchester

M8 5RB

North Manchester General Hospital, Manchester

NE1 4LP

Royal Victoria Infirmary and Freeman Hospital, Newcastle

WD18 0HB

Watford General Hospital, Watford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

Revimmune

INDUSTRY